Navigating the clinical trial landscape for vaccines with novel adjuvants

Adjuvants have the potential to improve current vaccines, and to make possible new vaccines. Dynavax technologies is considering the potential uses of adjuvant and working on designing a program to efficiently evaluate the relevant hypothesis tests, by working with expert agencies to identify most efficient path forward to registration. Focus is kept on clinical safety endpoints, but consideration is given …

Interested in vaccine clinical trials?

Vaccine clinical trials aim to establish the safety and efficacy of a vaccine prior to it being licensed. They offer protection to both the users and the manufacturers. Want to know more? Here are two presentations from the World Vaccine Congress Washington 2012! Novel strategies for improving early-stage vaccine clinical studies by Dr Doug Girgenti, Global Clinical Program Lead, Pfizer. …

Live event feed: Dr Thomas Fuerst

Blogged on behalf of Natalia Forero Serna Dr Thomas Fuerst, Executive Vice President, Chief Scientific Officer, PharmAthene presented today at the World Vaccine Congress Lyon to give details on the development of a robust manufacturing platform for production of a next generation anthrax vaccine. The production of this vaccine will be achieved through the use of modern vaccine production technologies …